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PREFACE
The objective of this study was to determine the incidence of unique gennline
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(SSCP) analysis. This thesis has been prepared as two chapters that have been submitted
as two manuscripts. The first manuscript was submitted with collaborators to Human
Mutation and the second manuscript was submitted to Cancer.
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CHAPTER I
INTRODUCTION
Researchers now recognize that a complex interplay ofgenetic) honnonal, and
environmental factors contribute to cancer susceptibility. Tumor suppressor genes playa
major role in hereditary predisposition to cancer. These genes are believed to control ceU
growth through mechanisms that are not yet fully understood. Two of the most
vigorously studied tumor suppressor genes are the retinoblastoma, Rb, and the breast
cancer susceptibility gene, BRCA 1.
The Rb gene was the first human tumor suppressor gene to be cloned and
sequenced (Friend et 811., 1986~ Fung et at) 1987~ Lee et 811., 1987). Inherited mutations
causing Joss of the Rb gene's function play an essential role in the etiology of
retinoblastoma and osteosarcoma (Benedict et 811., 1983; Bishop, 1991). Furthermore,
somatic defects leading to loss of the Rb gene's function are found in other cancers
including breast, ovarian, bladder, and prostate (Bookstein et 811., 1990; Horowitz et 811.,
1990; Lee et aI., 1990;. Bishop, 1991; Li et al., 1991).
In contrast, the BRCA 1 gene is one of the more recent tumor suppressor genes to
be identified. This gene has been positively linked to familial breast and ovarian cancers as
well as a lower percentage ofsporadic tumors in the same locations (Easton et 811., 1993 ~
Futreal et aI., 1994; Stekhen-Gersdorfet 811., 1994).
Ovarian cancer is the leading gynecological malignancy in the United States. Early
detection is extremely difficult because ofthe relative inaccessibility ofthe ovary (Gallion
et 811., 1995). As a r,esult, dinical prognosis is generally poor because most tumors are
usually discovered in later stages once metastasis has oocurred (Tsao et aI., 1991).
Ovarian cancer incidence is one-fifth to one-third lower in Japan than in the United States
(Herrinton et aI., 1994), however, the same obstacles to early detection ex.iist. In light of
this difficulty, one major focus in tumor suppressor gene research has been to identifY
mutations that could be used as a screening test for early detection.
The major objective of this r,esearch was to det,errnine whether a sample population
of Japanese women with ovarian cancer carry unique germJine mutations in the BRCAI
and Rb tumor suppressor genes.
This thesis has been prepared as two chapters: that have been submitted as two
manuscripts. Chapter II was submitted with collaborators to H1.1man Mutation and
Chapter III was submitted to Cancer.
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CHAPTER II
BRCA I GERMLINE MOTATION IN A JAPANESE
OVARIAN CANCER FAMILY
ABSTRACT
We analyzed 21 Japanese women diagnosed with ovarian cancer for BRCA 1
germline mutations using single-strand conformation polymorphism (SSCP). The women
were randomly selected without regard for a family history ofovarian cancer. We
identified one frameshift mutation, 797delAA, in exon 11 of the BRCAl gene in a woman
with a family history ofovarian cancer. BRCAl mutations have been shown to playa role
in breast and ovarian cancer in the United States where approximately 1.4% ofwomen
wiU develop ovarian cancer during their lifetime. In contrast, the cumulative incidence of
ovarian cancer in Japan is one-fifth to one-third that ofthe United States. Since this
mutation has only been seen once before, in a Japanese woman with breast cancer, this
data suggests that this mutation may only be carried in the Japanese population.
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INTRODUCTION
Ovarian cancer is the leading gyneco)ogicaJ malignancy in the United States.
Approximately 5-10% ofovarian canoers diagnosed in American women result from
hereditary predisposition with the remaining 90-95% believed to be ofsporadic origin
(Houlston et aI., 1991; Bewtra et aI., 1992; Lynch et aI., 1993). GermJine mutations in the
BRCAJ gene hav,e been linked to 40-50% offamilial breast cancers and 80% offamilial
breast-ovarian cancers (Easton et aI., 1993; Steichen-Gersdorfet al., 1994). Steichen-
Gersdorf and coworkers report evidence of linkage to the BRCA1 gene in an estimated
78% offamilies with hereditary or IIsite-specific II ovarian cancer. The criteria for being a
"site-specific" ovarian cancer family is three or more cases ofepithelial ovarian cancer and
no breast cancer cases diagnosed in anyone under the age of SO (Steichen-Gersdotf et al.,
1994). Alternatively, mutations in the BRCAJ gene in sporadic ovarian tumors have been
found to occur only in rare instances (Futreal et at., 1994).
The BRCA1 gene has been mapped to chromosome 17q21. It is composed of22
coding exons containing 5592 bp of sequence that is translated into a protein of 1863
amino acids. A highly conserved RING finger rnotifcontaining cysteine and histidine
residues in the arrangement Cys3-His-CYS4' lies at the NH2-terminus of the protein (Miki et
aI., 1994; Wu et at, 1996). RING finger motifs containing the same consensus sequence
are found in regulatory proteins, suggesting the BRCA1 protein may function in gene
transcription regulation (Wu et aI., 1996; Shattuck-Eidens et aI., 1995). In addition, the C-
terminus contains an excess ofnegatively charged amino acids that can activate
transcription ofboth yeast and mammalian cells when bound to a GAL4 binding domain
(Monteiro et aI., ] 996). Szabo and coworkers report that the 120 residues ofthe~-
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tenninus including the RING finger motif and the 80 residues of the C-tenninus are more
than 80% conserved between the human, canine, and murine BRCAJ gene sequences
supporting the theory that these regions are critical to gene function (Szabo et aI., 1996).
Frameshift and nonsense mutations that lead to premature protein truncation are
the most common mutations found in the BRCAl gene in breast and breast-ovarian cancer
families. Exon 1I contains 60% of the entire coding region ofthe gene and, to date, 55%
ofthe >100 currently reported mutations (Grade et aI., 1996). The other 45% of the
reported mutations are spread throughout the remaining 21 exons. The most cornman
mutation found in the BRCAI gene is a 2 bp deletion at base 185 in exon 2 (Simard et aI.,
1994; Shattuck-Eidens et at, 1995; Struewing et al., 1995). This deletion occurs with high
frequency in people of Ashkenazi Jewish descent. Recent studies report occurrences in the
British population (Berman et aI., 1996) and in Iraqi Jews (Sher et ai, 1996; Abeliovich et
aI., 1997). Abeliovich and cowor"kers believe the 185de1AG mutation was transferred to
the Iraqi Jews through a cornmon ancestor with Ashkenazi Jews approximately 2500 years
ago (AheJiovich et aI., 1997). When a genetically distinctive population, such as the
Ashkenazi Jews, can trace their ancestors back to a relatively isolated group offounders,
unique mutations or characteristics may appear at elevated incidence levels when
compared to the general population. This concept ofa "founder effect" has been used as a
likely explanation for the high incidence of the 185delAG mutation in the BRCAI gene in
the Ashkenazi Jews.
While the hereditary predisposition to ovarian cancer in Japan is equivalent to the
5-10% found in American women (Inoue et al.,. 1995), the overall incidence of ovarian
cancer in Japan is one-third to one-fifth that afthe United States· (Herrinton et aI., 1994).
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Japanese populations lack many of the dietary risks, such as a diet high in saturated fats
and frequent red meat consumption (Cramer et aI., 1984), commonly attributed to ovarian
cancer in the United States. This dietary difference has been used as one explanation for
the lower ovarian cancer incidence rates in Japan (Herrinton et at, 1994).
In this study, we used SSCP to screen exons 1,3, 11, 13, 16, 17, 18,21 and 22 of
the BRCAJ gene, including the intron-exon boundaries, in genomic DNA from 21
Japanese women diagnosed with various forms ofovarian cancer. OUf primary focus on
exon 11 was due to its extensive coding region (60%) and the fact that 55% of the
currently identified mutations are located in this exon. The other exons were selected
randomly across the gene.
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MATERIALS AND METHODS
Materials. Buffy coats from 21 Japanese women ranging in age from 19 to 61 and
diagnosed with various forms of ovarian cancer were obtained from the Tokyo Medical
College, Tokyo, Japan (Table 1).
DNA Extraction. Genomic DNA was extracted from the huffy coats and purified by
phenol-chloroform extraction (Sambrook et aI., 1989).
PCR-SSCP Analysis. Polymerase Chain Reaction (PCR) amplification of the genomic
DNA was performed using primers and primer conditions previously described (Friedman
et a1., 1994). PCR reactions were carried out in 50 pi volumes containing 50 ng genomic
DNA, lOX PCR Buffer (Boehringer-Mannheim, Indianapolis, IN), 200 flM each of dATP,
dGTP and dTTP, 20 IlM dCTP, 0.5 flCi [a_32p] dCTP [(3000 Ci/mmol)~DuPont NEN,
Boston, MA], 1 J.1M oreach primer and 1.25 U of Taq polymerase (Boehringer-
Mannheim, Indianapolis, IN). Amplification was accomplished with 35 cycles of 94°C, 45
s.; 55 or 60°C, 30 s; 72°C, 30s; with a 7 min extension at 72°C following the final cycle. A
4.5 J.lI aliquot of the PCR product was diluted in 25 III of denaturing loading buffer (95%
formamide, 10 mM Ethylenediaminetetraacetic acid, 0.05% bromophenol blue, 0.05%
xylene cyanol FF), heated at 99°C for 2 min then immediately cooled on ice. Aliquots of
4.5 I.d were then loaded onto a 0.5X Mutation Detection Enhancement gel (FMC
Bioproducts, Rockland, ME) and electrophoresed at room temperature for 18 hours at 8
W constant power. Following electrophoresis, gels were transferred to Whatman filter
paper and exposed to film for 24 hours at -70°C.
Sequencing. The aberrant band and a normal control were eluted from the gel and
reamplified with the appropriate primer pair. PCR products were purified for sequencing
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with a QIAquick Spin peR Purification kit (Qiagen, Santa Clarita, CA). Purified products
were bidirectionally sequenced using a model 373A automated fluorescence-based cycle
sequencer (Applied Biosystems, Foster City, CA).
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RESULTS AND DISCUSSION
We have screened 21 Japanese women diagnosed with several fonns ofovarian
cancer using SSCP analysis over 9 of the 22 exons in the BRCA1 gene including intron-
exon boundaries. Variant banding was discovered in patient one following PCR
amplification with primer pair 11 i (Figure 1). DNA sequence analysis of the aberrant band
revealed a heterozygous AA deletion in codon 797 creating a premature stop codon
downstream at codon 799 (Figure 2). The premature stop codon would be expected to
generate a truncated protein missing the 31 1065 amino acids. Truncated forms of the
BRCA J protein may be highly unstable as well as being nonfunctional. In 87% ofmutated
BRCAJ proteins, the C-terminus of the protein is absent (Couch et aI., 1996) supporting
the finding that this area contains an important functional domain (Monteiro et aI., 1996;
Szabo et aI., ] 996)..
The patient was diagnosed with ovarian cancer at age 61. A limited family history
revealed that the subject's mother was diagnosed with ovarian cancer at age 68. In
addition, eight of the mother's nine siblings were diagnosed with various fonns of cancers.
Unfortunately, further study of the inheritance of this mutation is not possible because of
unavailable living or archival tissue from the individuals previously mentioned.
This frameshift mutation was previously reported by Katagiri and coworkers in a
study of 103 Japanese breast cancer patients (Katagiri et aI., 1996). The study samples
were selected using criteria to identify women with a likely hereditary predisposition to
breast cancer. In that study, one pati.ent, with an unknown family history, displayed the
AA deletion at codon 797 (Katagiri et at, 1996).
The identification of this mutation in two Japanese individuals diagnosed with
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breast cancer and breast-ovarian cancer may indicate that this is an ethnically isolated
mutation similar to the 185DeiAG mutation in BRCAJ predominantly found in the
Ashkenazi Jewish population.. Additional screening of Americans with Japanese ancestry
may provide more infonnation on the incidence of the BRCA1 mutation reported here,
797delAA, in the Japanese population. Future studies are needed to further determine the
existence of unique mutations in cancer-related genes not only in Japanese populations but
also other geographic and/or ethnic groups exhibiting distinctive high or low incidence
rates of cancer. Identification ofmutations in the BRCA I gene as wen as other cancer
related genes that are expressed in specific groups of individuals may be useful in genetic
counseling and preventive screening.
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TABLE 1. lAPANESE OVARIAN CANCER PATIENT CHARACTERISTICS
Patient Age of onset Ovarian Tumor Pathology Family History
1 61 Unknown (also breast cancer) Mother-ovarian (age 68);
8 of mother's 9 siblings
-various cancers
2 44 Mucinous none
3 33 Mucinous none
4 19 Serous none
5 50 Clear Cell (also breast cancer) none
6 22 Mucinous none
7 22 Yolk Sac none
8 19 Dysgerminoma none
9 44 Endometroid ~ none
10 43 Clear Cell none
11 42 Mucinous none
12 55 Unknown Sister-ovarian; Brother-
rectal
13 32 Yolk Sac none
14 48 Malignant teratoma none
15 56 Clear Cell none
16 40 Endometroid none
17 45 Serous Mother-ovarian
18 >45 Unknown none
19 44 Unknown none
20 >45 Unknown none
21 45 Unknown none
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FIGURE 1. BRCAJ FRAMESIDFT MUTATION IDENTIFIED IN PATIENT 1 BY
SSCP
12345&7B 9 10 11 IZ 13 1.t is 16 17 18 19 lil 21
Excn 11
Fragment i
is
fIGURE 2. SEQUENCE CHANGE IN EXON 11, FRAGMENT i DUE TO
FRAMESillFT MUTATION, 797delAA
Patient 1:
Control:
ACA GCC AAA TAA
Thr Ala Lys Stop
ACA GAA CCA AAT
Thr Glu Pro Asn
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CHAPTERllI
LACK OF GERMLINE MUTATIONS INDICATES Rb GENE IS NOT INVOLVED IN
HEREDITARY PREDISPOSITION TO OVARIAN CANCER IN JAPANESE WOMEN
ABSTRACT
Background: In the United States approximately 1.4% of women will develop ovarian
cancer during the~r lifetime. In contrast, the cumulative incidence ofovarian cancer in
Japan is one-fifth to one-third that of the United States.
Methods: We analyzed 21 Japanese women diagnosed with ovarian cancer for gerrnline
mutations in the retinoblastoma (Rb) gene using single-strand conformation polymorphism
(SSCP) analysis. The women ranged in age from 19 to 61 and were randomly selected
without regard for a family history of ovarian cancer.
Results: Results of the SSCP analysis of the samples yielded no mutations in the exon
regions but one sequence alteration in an intronic region.
Conclusions: Al]eHc loss of the Rb gene has been reported in up to 52% of ovarian
tumors, however, the existence ofgermline mutations in the Rb gene leading to ovarian
cancer predisposition has not been investigated. The lack ofgermline mutations in the
sample Japanese population provides strong evidence that mutations in the Rb gene do not
playa part in the hereditary predisposition to ovarian cancer.
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INTRODUCTION
Ovarian cancer is the leading gynecological malignancy in the United States.
Clinical prognosis is generally poor once the cancer is discovered1 because the
inaccessibility of the ovary makes early detection difficult2• Approximately 5-10% of
ovarian cancers diagnosed in American women result from hereditary predisposition with
the remaining 90-95% believed to be of sporadic origin3.s. Several tumor suppressor genes
have been positively linked to hereditary ovarian cancer, including BRCAl and BRCA26-9.
The retinoblastoma (Rb) tumor suppressor gene has been reported to exhibit allelic loss in
30-52% of ovarian tumors1Q-12. Nevertheless, a link to hereditary predisposition ofovarian
cancer through germline mutations in the Rb gene has yet to be investigated.
TheRb gene is mapped to human chromosome 13 in the 13q14.2 region. TheRb
gene contains 27 exons whi,ch are process,ed to produce an mRNA 4700+ basepairs in
length13- IS • The mRNA is translated into a nuclear phosphoprotein approximately 110 kDa
,
in size16. The protein is hypophosphorylated as the cell enters G1, becomes
phosphorylated late in G1 and remains hyperphosphorylated through S, G2 and most of
M, then reverts back to a hypophosphorylated state at the M-G1 transition17.
Phosphorylation of the protein at the GI-S transition is believed to be controlled by at
least three different cyelin-dependent kinaseslS. Cell growth takes place during the
hyperphosphorylation of the Rb protein. Growth suppression, on the other hand, occurs
during the G1 phase of the cell cycle when the protein is hypophosphorylated18. While
hypophosphorylated, the Rb protein has been shown to bind and inhibit transcription
factor E2F17. Recent studies also report Rb protein interactions with a number of other
proteins during the G1 phase. The exact mechanism by which Rb regulates gene
18
-expression and cellular growth however remains to be elucidated.
While the hereditary predisposition to ovarian cancer in Japan is equivalent to the
5-10% found in American womenl.9, the overall incidence ofovarian cancer in Japan is
one-third to one-fifth that orthe United States20. Japanese populations lack many ofthe
dietary risks, such as a diet high in saturated fats and frequent red meat consumption21>
commonly attributed to ovarian cancer in the United States. This dietary difference has
been used as one explanation for the lower ovarian cancer incidence rates in Japan20 .
Mutations in the Rb tumor suppressor gene have an effect very early in a carrier's
life. Approximately 90% ofthe individuals who inherit a defective all,ele will lose the
second allele to a somatic mutation and develop retinoblastoma before age three. In the
breast and ovarian cancer susceptibility genes, BRCAl and BRCA2, on the other hand,
loss of the second allele appears to occur later in life. In all cases, this second hit is not yet
fully understood. Age dependent penetrance is observed in women with inherited
mutations in either BRCAJ or BRCA2, with the risk of ovarian cancer increasing from
23% at age 50 to 63% by the age of70 in the case ofmutations to BRCAP2. The presence
ofmutations with variable penetrance would suggest a mechanism responsible for age
variation in disease onset. SpecificaUy, missense mutations may occur in less critical areas
of the gene that may not immediately ,effect protein function in contrast to frameshift and
missense mutations that lead to protein truncation. In ~ddition, Gayther and coworkers
have proposed that there exists a genotype-phenotype correlation in both BRCA 1 and
BRCA2 between the location ofmutations within each gene and the onset of either breast
or ovarian carcinoma23,
Should such an age bias or genotype-phenotype correlation ,exist in the Rb gene,
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the effect of gennline mutations may not be limited to retinoblastoma. As a preliminary
test ofthis hypothesis, we have examined a set of ovarian cancer patients for inherited
mutations in the Rb gene. Should weakly penetrant alleles or selectively located mutations
allow individuals to bypass retinoblastoma as a child, it is possible that the mutant Rb
tumor suppressor gene could lead to cancer in other tissues later in life. Examination of
such tumors might provide insight into the mechanisms by which second hits occur. Since
few individuals are expected to develop, cancers as a result of this pathway, the best
mechanism by which to identify such occurrences is through genomic examination of
individuals with various forms of cancer for which genetic causes, i.e. BRCAJ mutations,
have yet to be determined. Ovarian cancer is a potential candidate for association with Rb
in light of the 30-52% incidence ofallelic loss in ovarian carcinomasl G-12.
In this study, we used single-strand conformation polymorphism (SSCP) analysis
to screen all exons, including intron-exon boundaries of the Rb gene, in genomic DNA
from 21 Japanese women diagnosed with several forms ofovarian cancer.
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MATERIALS AND MEmODS
Materials. BufTy coats from 21 Japanese women ranging in age from 19 to 61 and
diagnosed with various forms ofovarian cancer were obtained from the Tokyo Medical
College, Tokyo, Japan (Table 1).
DNA Extraction. Genomic DNA was extracted from the butlY coats and purified by
phenol-chlorofonn extraction24.
PCR-SSCP Analysis. PCR amplification ofthe genomic DNA was performed using
primers developed in our lab (Table 2). Primers were developed in the intronic regions
flanking each exon. Due to its 1.8kb size, exon 27 was screened using nine sets of
overlapping primers. Primers for exons 1 and 21 were used as pubHshed by Hogg and
coworkers and Liu and coworkers25, 26. PCR reactions were carried out in 25 J.l1 volumes
containing 50 ng genomic DNA, lOX PCR Buffer (Boehringer-Mannheirn, Indianapolis,
IN), 200 JlM each ofdATP, dGTP and dTTP, 20 JlM dCTP, 0.5 J.lCi [a_32p] dCTP [(3000
Ci/mmol); DuPont NEN, Boston, MA], I JIM ofeach primer and 1.25 U of Taq
polymerase (Boehringer-Mannheim, Indianapolis, IN). Amplification was accomplished
with 35 cycles of 94°C, 45 s; TM, 30 s; 72°C, 30s; with a 7 min extension at 72°C
following the final cycle. A 4.5 III aliquot ofthe PCR product was diluted in 25 J.d of
denaturing loading buffer (95% formamide, 10 mM EDTA, 0.05% bromophenol blue,
0.05% xylenecyanol FF), heated at 99°C for 2 min then immediately cooled on ice.
AHquots of4.5 III were then loaded onto a 0.5X Mutation Detection Enhancement gel
(FMC Bioproducts, Rockland, ME) and electrophoresed at room temperature for 14
hours at 6 W constant power. Following electrophoresis, gels were transferred to
Whatman filter paper and exposed to film for 24 hours at -80°C.
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Sequencing. The aberrant band and a nonnal control were eluted from the gel and
reamplified with the appropriat,e primer pair. peR products were purified for sequencing
with a QIAqukk Spin PCR Purification kit (Qiagen, Santa Clarita, CA). Purified products.
were bidirectionally sequenced using a model 373A automated fluorescence-based cycle
sequencer (Applied Biosystems, Foster City, CA).
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RESULTS
We have screened 21 Japanese women diagnosed with several fonns of ovarian
cancer using SSCP analysis over all 27 exons in the Rb gene including intron-exon
boundaries. Variant banding was discovered in patient six following PCR amplification
with primer pair 22 (Figure 1). DNA sequence analysis yielded no sequence changes in the
exon or the portion ofthe 31 intran contained within the region amplified by the primer
pair. Therefore we assume that the base change fell within the intran region 51 ofthe
exon. This particular region has a tandem repeat of24 T residues that has made
identifYing the exact base change difficult. Moreover, the tandem repeat may actuaUy be
the site of the alteration by leading to DNA polymerase slippage during transcription. The
potential biological significance of this change is not clear however, since it is located
outside of the splicing-donor and acceptor sites.
The patient was diagnosed with mucinous ovarian cancer at age 22. Diagnosis of
any form of ovarian cancer prior to age 45, particularly in someone this young, is
considered a strong indicator of hereditary ovarian cancer. Unfortunately, no family
history or tissue samples from family members are available for further screening.
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DISCUSSION
Rb gene mutations have been identified in a variety of diverse human cancers
including retinoblastoma13•1S,27. osteosarcomasl3• small cell lung carcinoma28• breast cancer
29,30. bladder cancerI, 32. and prostate cancer3. These mutations are primarily small
deletions and point mutations located between exons 12 and 23. which encode the binding
regions potentially involved in the suppression of cell growth33. The widespread incidence
ofRb gene mutations in such diverse cancers illustrates the prime importance of the gene
in cancer progression.
Only two mutations have been reported in ovarian tumor DNA to date. Takano
and coworkers report a C to A transition at codon 621 leading to the substitution ofan
arginine for a serine in a woman with advanced clear cell adenocarcinoma of the ovary34.
However. this mutation was also found in normal tissue and therefore was disregarded as
a polymorphism unrelated to the cancer. Liu and coworkers describe the deletion ofexon
21 in its entirety in a woman displaying loss of one allele and duplication of the remaining
one3S , Exon 21 is believed to encode a portion of SY-40T antigen binding region
important in the cell growth regulatory function of the Rb gene33.
However, the majority ofRb gene studies in ovarian cancer have involved
screening of tumor DNA using immunohistochemical techniques which do not reveal
molecular abnormalities including gene mutations or defects to phosphorylation sites36.
Takano and coworkers report an increase from 7% to 50% incidence of allelic loss at the
Rb locus from early stage to advanced stage tumors34. Furthermore, Kim and coworkers
found allelic loss of the Rb locus associated with tumors having invasive or metastic
ability37. These results have led to the theory that loss of the gene's function through
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somatic mutations may be important in the progression ofovarian cancer rather than the
initiation34• This theory has also been proposed by Kubota and coworkers with regard to
the progression ofprostate tumors33 .
OUf results suggest that germJine mutations in the Rb gene are not present in
ovarian carcinomas and therefore do not pr1edispose women to hereditary ovarian cancer.
Thus, future study ofthe Rb gene should focus on the role that somatic mutations to the
gene ha¥e in the progression ofovarian cancer.
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TABLE 1. JAPANESE OVARIAN CANCERPATlENT CHARACTERISTICS
Patient Age of onset Ovar"an Tumor Pathology Family History
1 61 Unknown (also breast cancer) Mother-ovarian (age 68)~
8 ofmother1s 9 siblings
-various cancers
2 44 Mucinous none
3 33 Mucinous none
4 19 Serous none
5 50 Clear Cell (also breast cancer) none
6 22 Mucinous none
7 22 Yolk Sac none
8 19 Dysgerminoma none
9 44 Endometroid none
10 43 Clear Cell none
II 42 Mucinous none
12 55 Unknown Sister-ovarian; Brother-
rectal
13 32 Yolk Sac none
14 48 Malignant teratoma none
15 56 Clear Cell none
16 40 End0 metroid none
17 45 Serous Mother-ovarian
18 >45 Unknown none
19 44 Unknown none
20 >45 Unknown none
21 45 Unknown none
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TABLE 2. Rb GENOMIC DNA PRIMER PAIRS
Exon Forward Primer (5' -3') Reverse Primer (5'-3') TmoC Size
1p* GATCCCAAAAGGCCAGCAAGTGTCT TCAACGTCCCCTGAGAAAAACCGGA 62 570
1** AGCTCGCTGGCTCCCGCCGCGGAAA TCCCGCGTGAGGGACGCGCTCTGCT 62 200
2 GTGTTATGTGCAAACTATTG GGTAAATTTCCTCTGGG 58 358
3 GCCATCAGAAGGATGTGTTAC CATTTCCTTTTATGGCAGAGG 56 312
4 CCTTCCAAAGGATATAGTAGTG CCCAGAATCTAATTGTGAACAA 52 329
5 TGAATAAAGCATGAGAAAA CGATCAAACTAACCCTAAC 50 209
6 TGCACAAAAAGAAACACC CAGAGAATGAGGGAGGAG 61 278
7 CATGCTGATAGTGATTGTTGAATG GCCTTAGAACCATGTTTGGTAC 58 314
8 TGGATGTACAATTGTTCTTATC ATATTGTTAGGGAGAACTTAC 47 252
9 TTGACACCTCTAACTTACCCT ACAATTATCCTCCCTCCACA 60 235
10 GAAATCTGTGCCTCTGTGTG CTAAAGGTCACTAAGCTAAAGA 60 277
11 GCATAAAGCACAAATT TGGCCTTCAATATATAT 51 261
w 12 TAGAGACAAGTGGGAG TACATGTTAGATAGGAGAT 49 321
.....
13 ACAGTATCCTCGACATTGA TACACAGGCAGCAGGGA 60 299
14 TGCCTATAATCCCAGCCTCT TGATCTTGATGCCTTGACCTC 68 340
15 TTCACCCCAGCCTGGCA ACAACCTCAAGAGCGCACG 61 302
16 GAAGAAGAACGATTATCC TCCTTCTCCTTAACCTC 55 293
17 TCCAAAAAAATACCTAGCTC GTAGATTTGTTAAGAAACACCTC 51 350
18 TTTTGATATGTACCTGGG CTATTCCCTACAGTTTCTT 55 270
19 CTGTGATTCTTAGCCAACTT ACATGATTTGAACCCAGTC 51 262
20 AGAGTGGTAGAAAAGAGGT ACAAGTAAGTAGGGAGGAG 56 326
21 * GACTTTCAAACTGAGCTCAGTATGG ACAAATACCTGCTTATTACAGGGAT 58 518
22 AATATGTGCTTCTTACCAGTC GTGGACCCATTACATTAGAT 50 299
23 TTTGCAGTATGCTTCCACCA AATAATCCCCCTCTCATTCTTT 57 328
24 GTATTTATGCTCATCTCTG CAATATGCCTGGATG 52 222
25 TGCTAACTATGAAACACTG TGCTGAGACTCTGGATT 53.1 268
26 GCATAAAGTAAGTCATCG GACCTTCATTTTACATCA 44 336
Exon
27a
27b
27c
27d
27e
27f
27g
27h
27i
Forward Primer (5' -3')
CACTTGCCAACTTACCC
GATGTGACTGTATAACTTTCCC
AAGTTGTAGCAGATTGTTTCCTC
GCCTGTCTGACTACTTTGCC
GGAATCTGATATACTGTGTGC
GACCCTAACACAGTATATCCCA
TCTCAAAATTATTCTGCCCTC
TCCCCTCCCCTACACCTAAAG
AGGGCTTACTATTTCTGGG
Reverse Primer (5'-3')
CTGCACATTTTATATCCACA
TATCAGGACTCCCACTCTAG
GCATTTGGAAGATAGATAGGACAC
GGTTATACTTTGCTTCCAGC
CAGGACCCAGAAACATTAG
GCCTAACCCATAATGACCCT
GCTGAAGCTACCTTAAATATCC
ATCTCTGAAGTTCCTAAAATTCTGGC
AGGAATGGATGAGATACTAGG
TmoC
53
53
68
61.5
51
55.4
55.4
62
52.5
Size
271
263
226
324
324
346
374
389
332
I..V
N
The names of the primer pairs used to screen the Rb gene by SSCP analysis are listed in the first column. Tm indicates the annealing
temperature for each PCR primer pair. The size of the product is given in basepairs. Primer pairs annotated by * are as reported by
Hogg and coworkers (1992), and ** are as reported by Liu and coworkers (1995).
-.FIGURE 1. POTENTIALRb SEQUENCE CHANGE IDENTIFIED IN PATIENT 6 BY
SSCP
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CHAPTER IV
CONCLUSION
This project identified two sequence alterations, a frameshift mutation in the
BRCAJ gene and a potential insertion or repeat in an intronic region of the Rb gene. Due
to its location in an intronic region, the biological significance ofthis Rb sequence change
is unclear. On the other hand, the BRCAJ mutation, 797delAA, may represent an
ethnically isolated mutation, similar to the BRCAI mutation 185delAG in Ashkenazi Jews,
that could be used for early detection screening.
From these studies it is relatively clear that the Rb gene plays little or no role in the
hereditary predisposition to ovarian cancer in Japanese women. lfowever, further study of
the BRCAJ gene and in particular, the penetrance of the 797delAA mutation, is
recommended. Moreover, due to the low incidence ofgermline mutations in the BRCA J
and Rb genes in the sampte population, future studies of the Japanese should focus on
other tumor suppressor genes such as the BRCA2 that may be responsible for hereditary
ovarian cancer in the population.
As more mutations are identified, researchers have begun to debate the many
ethical issues that surround genetic screening and the participating families. However, in
light of the low survival rate following ovarian cancer, prescreening individuals may help
further the fight against this disease and greatly reduce the risk in women with a family
history ofovarian cancer.
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